Mutabilis - Pipeline

Pipeline

At Mutabilis, we develop a novel class of antibacterials named Dabocins and derived from the non-natural Diazabicyclooctane scaffold.

Like β-lactams, Dabocins inhibit the Penicillin-Binding Proteins (PBP).
Unlike β-lactams, Dabocins show an exceptional stability to class A, B, C, D β-lactamases.

As such, Dabocins have the potential to reset decades of resistance to β-lactams.

Our pipeline includes two Dabocin programs.

Project

Stage

Support

EBL-1463 (i.v.)
Carbapenem-resistant Enterobacterales

Lead op.

Preclinical

Phase I

2G-DAB (i.v.)
Carbapenem-resistant Enterobacterales
Carbapenem-resistant Pseudomonas
Carbapenem-resistant Acinetobacter

Lead op.

Preclinical

Phase I

EBL-1463

EBL-1463 is a potential first-in-class representative of the Dabocin family, entering preclinical development against Carbapenem-resistant Enterobacterales. This compound exhibits unrivaled stability to any class A, B, C and D β-lactamase. Furthermore, it is not affected by the concerning PBP3 mutations recently observed in E. coli (Alm et al., 2015) which weaken the activity of cephalosporins and monobactams. This program is supported by CARB-X.

2G-DAB

This Lead-to-Candidate program aims at identifying next generation Dabocins inhibiting not only Carbapenem-Resistant Enterobacterales, but also Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii.
This program is run in collaboration with Roche.